ABSTRACT
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INTRODUCTION
The desire of both women and doctors to avoid unnecessary procedures during pregnancy is the driving force behind the search for optimal screening strategies and, more recently, non-invasive prenatal testing of cell-free fetal DNA. The most important factor influencing uptake of invasive procedures (chorionic villus sampling (CVS) and amniocentesis) is the procedure-related fetal loss rate (FLR) 1 , which is calculated as the total FLR minus the spontaneous FLR. The latter is influenced by the maternal risk profile (age, weight, parity and obstetric history) procedure-related risk depends on the technique and instruments used, possible technical difficulties and operator experience 4, 6, 7 . As a result of interaction between these variables, the total FLR can vary greatly 8 . In the literature, procedure-related FLR ranges from 0.06% to > 1.0% for both CVS and amniocentesis 4, 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Most studies are observational and include mixed populations. Of the few published randomized controlled trials, Tabor et al. compared FLR in women who underwent amniocentesis with a control group, showing a 1% higher FLR in women who underwent amniocentesis 10 . The literature suggests that transabdominal (TA) CVS and amniocentesis have smaller risks than previously thought, comparable to that of spontaneous risk 11, 12, 14, 21 . It remains a challenge to report realistic risk figures, taking into account all variables that influence the procedure-related FLR. Furthermore, some of the abovementioned studies were performed years ago, at a time when ultrasound systems were less advanced and techniques and training in invasive procedures less standardized. A recent meta-analysis showed that accurate estimates of current procedure-related risks of invasive procedures are lacking 5 . Many experts believe that procedure-related risks need re-evaluation 22 . A new consensus should be reached to avoid discrepancies in information given among centers.
The aim of this study was to identify maternal-, operator-and procedure-related risk factors that affect the overall estimated FLR and to compare fetal loss among subgroups of women according to the examination undertaken in order to calculate the total spontaneous FLR and the procedure-related FLR after CVS and amniocentesis.
METHODS

Study design
This retrospective cohort study on spontaneous and procedure-related fetal loss in women who underwent CVS and/or amniocentesis was conducted at two university medical centers: the University Medical Center Groningen in Groningen and the Academic Medical Center in Amsterdam, The Netherlands. Data on all consecutive singleton pregnancies that had undergone CVS and/or amniocentesis between 1 January 2001 and 31 December 2011 were retrieved from the databases of both hospitals. The same data were retrieved for women who had undergone a combined test at 11-14 weeks and/or a fetal anomaly scan at around 20 weeks of gestation.
Both academic hospitals are referral centers but also have a low-risk population. Prenatal screening is offered to women in the form of the combined test and/or the 18-20-week anomaly scan. According to the national guideline, women in The Netherlands undergoing CVS or amniocentesis are always referred to a tertiary hospital. As a consequence, this study included both low-risk and referred women.
The cohort of women was divided depending on the examination(s) that they had undergone into the following five groups: (1) combined test (and 20-week anomaly scan); (2) 20-week anomaly scan only; (3) transcervical (TC) or TA-CVS; (4) amniocentesis; (5) amniocentesis after an unsuccessful CVS.
For all cases, information was available on procedure-related characteristics (indication, operator experience, technique) as well as maternal characteristics, obstetric history and pregnancy outcome.
Definitions
Pregnancy outcome was classified into the following categories: alive, miscarriage, preterm labor and loss at 24-37 weeks, intrauterine fetal demise (IUD), termination of pregnancy (TOP), fetal loss during labor or neonatal death (NND). Alive was defined as a newborn showing signs of life after delivery. Miscarriage was defined as spontaneous death of the fetus before 24 weeks of gestation. Preterm labor and loss was defined as spontaneous delivery between 24 and 37 weeks of gestation with loss of the neonate. IUD was defined as fetal death ≥ 24 weeks, prior to delivery. Fetal loss during labor was defined as intrapartum death ≥ 24 weeks. NND was defined as infant death before 28 days of age.
In order to calculate the crude procedure-related FLR, the rate of spontaneous fetal loss was calculated separately for the two groups of women aged ≥ 36 years who did not have an invasive procedure and had undergone either the combined test (and the 20-week anomaly scan) or the 20-week anomaly scan only. Total spontaneous FLR was defined as the total number of fetal losses after ultrasound examination (11-14 weeks for the combined test and 18-20 weeks for the anomaly scan) and before 24 weeks of gestation (miscarriage). After 24 weeks of gestation, total spontaneous FLR was defined as the sum of cases with preterm labor followed by loss and IUDs. Spontaneous FLR was then compared with FLR in women who had undergone either TC-or TA-CVS or amniocentesis for indication of advanced maternal age only, without known a-priori risk factors. Procedure-related FLR was calculated as the total number of fetal losses before 24 weeks of gestation in women with an invasive procedure (CVS and/or amniocentesis) for advanced maternal age minus the background risk (spontaneous FLR). Because of the current system in The Netherlands, in which some women have an ultrasound examination at 11-14 weeks (combined test) and some at 18-20 weeks (anomaly scan), the 'starting point' was not the same for all women. In order to make comparable groups, FLR after ultrasound examinations and invasive procedures were compared: combined test vs CVS and 20-week anomaly scan only vs amniocentesis.
Operator experience of performing invasive procedures was classified according to the total number of procedures they had performed. For CVS, operator experience was classified as: Level 1, < 50 procedures; Level 2, 50-150 procedures; and Level 3, > 150 procedures. For amniocentesis, operator experience was classified as: Level 1, < 50 procedures; Level 2, 50-150 procedures; Level 3, 151-500 procedures; and Level 4, > 500 procedures.
The number of procedures and attempts carried out were classified as: one procedure with one attempt; one procedure with more than one attempt; and more than one procedure.
Statistical analysis
To compare differences in categorical variables between women who did or did not undergo CVS and/or amniocentesis, the chi-square test or Fisher's exact test was used, as appropriate.
Associations between single covariables and pregnancy outcomes were assessed by univariate binary logistic regression and expressed as odds ratios (ORs) (95% CI). Correlations of variables were used to check for confounders and interactions. Multiple binary logistic regression analysis (backward stepwise elimination method) was performed to evaluate the adjusted impact of covariables. Statistical significance was defined as P < 0.05 (two-sided). All statistical analyses were conducted using SPSS Statistics 17.0.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
In total, 36 350 cases were available for analysis, but only cases with known outcome (n = 29 201, 80.3%) were included. The population was divided into five main groups according to the examination(s) they had undergone: 9651 women had a combined test (and 20-week anomaly scan); 6432 had a 20-week anomaly scan only; 4862 had CVS (2029 TA and 2833 TC, of which 1787 were by forceps and 1046 by cannula); and 7970 had amniocentesis. In 286 cases, both CVS and amniocentesis were performed ( Figure 1 ). Table 1 shows the baseline characteristics in all groups. Women opting for CVS or amniocentesis were, on average, older (P < 0.01) and were more frequently parous (P < 0.01) and smokers (P < 0.01) than those without an invasive procedure.
Results of the multiple regression analyses to identify variables associated with FLR after an invasive procedure are presented in Tables S1 and S2. In women undergoing TC-or TA-CVS, variables significantly associated with a higher risk of fetal loss were repeat attempts during the procedure, the use of a TC cannula, gestational age of ≥ 13 weeks and pregnancy after assisted reproductive techniques (Table S1 ). In women undergoing amniocentesis, variables significantly associated with a higher risk of fetal loss were repeat attempts during the procedure, presence of a fetal anomaly and a family history of congenital anomalies (Table S2) . Table S3 shows the pregnancy outcome in each group, including all variables and indications. The total FLR before 24 weeks' gestation in women with a combined test (and 20-week anomaly scan) was 1.21% and in women with TC-and TA-CVS was 3.14%, giving a procedure-related risk of fetal loss of 1.93% or 1 : 52 for CVS. This percentage includes all indications for an invasive CVS, irrespective of the CVS technique used. The total spontaneous FLR before 24 weeks' gestation in women with a 20-week anomaly scan only was 0.31% and in women with amniocentesis was 1.56%, giving a procedure-related risk of fetal loss of 1.25% or 1 : 80 for amniocentesis. On univariate analysis, there was a trend between increased level of operator experience and lower FLR. These estimates include all indications for amniocentesis. Table 2 shows the pregnancy outcome for each group, stratified according to indication for the examination. The total spontaneous FLR in women aged ≥ 36 years who underwent the combined test was 1.40% (n = 63). For women who underwent TC-or TA-CVS indicated for advanced maternal age, total FLR was 2.76% (n = 40) and 2.43% (n = 13), respectively (P < 0.01). The additional risk of fetal loss from TC-CVS was therefore 1.36% or 1 : 74 and from TA-CVS was 1.03% or 1 : 97 (P = 0.06). When TC-CVS was performed by forceps the additional risk was 0.27% (1.67 -1.40%) and when performed by cannula it was 3.12% (4.52 -1.40%). When the number of procedures and attempts for (TC and TA) CVS were taken into account, the additional risk was 1.07% (2.47 -1.40%) when only one procedure and one attempt were performed and 4.48% (5.88 -1.40%) when more than one attempt was performed during the same procedure. No risk could be calculated for the group in which more than one procedure and more than one attempt were performed because the cohort was too small (n = 8 with no fetal loss).
The total spontaneous FLR in women aged ≥ 36 years who underwent the 20-week anomaly scan only was 0.63% (n = 2). For women who underwent amniocentesis indicated for advanced maternal age, total FLR was 1.11% (n = 60) (P = 0.325). The additional risk of fetal loss from amniocentesis was therefore 0.48% or 1 : 208. In women younger than 36 years who underwent the 20-week anomaly scan only, total FLR was lower at 0.52% (P = 0.79). When the number of procedures and attempts for amniocentesis were taken into account, the additional risk was 0.34% (0.97 -0.63%) when only one procedure and one attempt were performed, 1.34% (1.97 -0.63%) when more than one attempt was performed during the same procedure and 5.25% (5.88 -0.63%) when more than one procedure and more than one attempt were performed.
With increasing operator experience, FLR after TA-CVS decreased. The risk of procedure-related loss was 2.24% (3.64 -1.40%) at operator experience Level 1, 1.65% (3.05 -1.40%) at Level 2 and 0.42% (1.82 -1.40%) at Level 3 ( Figure 2a) . The risk after TC-CVS by forceps could not be calculated for operator experience Levels 1 and 2 due to the relatively low number of women and no fetal losses. At Level 3, the risk was 0.44% (1.84 -1.40%) (Figure 2b) . When using the cannula for TC-CVS, risk was 0.68% (2.08 -1.40%) at Level 1, 1.57% (2.97 -1.40%) at Level 2 and 6.85% 
DISCUSSION
This study shows that the procedure-related FLR in women aged ≥ 36 years who underwent TC-CVS on maternal age indication was 0.27% or 3.12%, depending on whether forceps or a cannula was used, respectively. For a TA approach, the procedure-related FLR was 1.03%. Factors influencing FLR after CVS were the use of a TC cannula (OR, 3.0), repeat attempts during the procedure (OR, 2.5), gestational age of ≥ 13 weeks (OR, 3.2-4.1) and pregnancy after assisted reproductive techniques. Procedure-related pregnancy loss after amniocentesis in women aged ≥ 36 years was 0.48%. Factors influencing FLR after amniocentesis were repeat attempts during the procedure (OR, 2.9), presence of fetal anomalies (OR, 8.5) and a family history of anomalies (OR, 5.0). Furthermore, the influence of operator experience on iatrogenic fetal loss was confirmed 4, 23, 24 . This study confirms the negative effect of variables such as structural anomaly on total FLR (including TOP) after amniocentesis. This factor is, by far, more predisposing to pregnancy loss than is advanced maternal age 5, 9, 25 . This retrospective study shows that the previously quoted 1.0% risk of fetal loss after amniocentesis does not reflect current practice. The risk of fetal loss after an invasive procedure seems to be lower (0.17-0.52%) when performed by an operator with more experience (Level 3 for both CVS and amniocentesis), which is in line with previous findings 4,5,9,10,23,26 , except when the procedure involved a cannula.
A strength of this study is that it includes a large population of women undergoing invasive procedures for different indications and two control groups. A limitation is its retrospective nature and, in the attempt to create similar groups and exclude possible bias, some groups included only few patients or fetal losses. Although the only way of confirming the conclusions of this study would be to perform a prospective randomized study, this is nowadays ethically unfeasible 22, 27 . Furthermore, we were unable to retrieve follow-up data in 20% of cases, which were excluded from the analysis. We did not opt for the possibility of imputation of data and chose to stay as close to the original data as were registered in the first instance. In our experience, outcomes that are frequently missing from the database are normal as caregivers tend to report fetal loss, especially iatrogenic loss. Although we cannot be certain, it is likely that we overestimated the risk of fetal loss rather than underestimated it.
Regarding first-trimester invasive procedures, it is clear that TC-CVS with forceps and TA-CVS should be the preferred methods of choice. A Cochrane review on CVS did not show convincing evidence to favor TA-CVS over the TC technique 6 . In contrast, Smidt-Jensen et al. and Chueh et al. showed a significant difference in risk between the two techniques, prompting abandonment of TC-CVS in their centers 11, 28 . This study shows that, depending on the technique used, both TA-and TC-CVS can have low FLR.
In our study, TC-CVS was the technique used in earlier years. Only since the introduction of first-trimester screening has the TA approach become more widespread. The rationale for using TC-CVS is that it allows for a larger sample to be obtained, which is especially useful for DNA analysis, and that it can be performed from 11 weeks onwards. We confirm that the FLRs after TCand TA-CVS seem to be comparable, however, only when forceps are used for TC-CVS 11, 28 . The higher FLR associated with the cannula for TC-CVS, irrespective of the operator experience, is possibly due to the abandonment of the previous cannula, which was withdrawn from the market, and use of a new, less flexible cannula in one of the two centers in 2008. Since 2010, this center also adopted the use of forceps for TC-CVS and implemented the TA approach. The advantage of being skilled in both techniques enhances the chance of successful sampling irrespective of placental location or position of the uterus. Operators performing TC-CVS should be trained preferably to use forceps. As suggested in the literature, growing experience with CVS techniques has the potential to lower FLR to a level similar to that for amniocentesis 11, 12, 14, 21 . One of the concerns with comparing women aged ≥ 36 years who underwent amniocentesis at around 16 weeks with a control group of women who underwent only the 20-week anomaly scan is the possible effect of the 2-4 weeks difference in gestational age on the spontaneous FLR, with possible overestimation of the procedure-related FLR at the time of the procedure 22, 27 . Surprisingly, after adjustment for gestational age (including only loss between 16 and 23 weeks), we found the same trend of lower FLR after amniocentesis compared with after the 20-week anomaly scan. The background FLR in this study (0.63% for women aged ≥ 36 years) falls within previously reported percentages that vary between 0.2% and 1.16% 20 . Similarly, the low risk of procedure-related loss after amniocentesis performed by an experienced operator is in line with recent studies with large cohorts and experienced operators 5, 13, 16, 23 . A large national population-based study in Denmark showed that neither TA-CVS nor amniocentesis was associated with a higher FLR in comparison with the control group, suggesting that the procedure-related FLR is very low for both CVS and amniocentesis 29 . Appropriate training of new operators under experienced supervision or by the use of training models can minimize the learning-curve effect and increase the success rate of invasive procedures 28, 30 . In our study, more than one needle insertion during a procedure was associated with an increased risk of fetal loss. Silver et al. showed that there is a direct relationship between operator caseload and sampling efficiency 31 . With the declining numbers of CVS and amniocentesis due to the widespread use of cell-free fetal DNA screening, a new directive on the number of operators performing invasive procedures and a minimum caseload per operator should be defined by a professional society. In The Netherlands, the Dutch Society for Obstetrics and Gynecology recommends a minimum number of 30 procedures per operator per year 32 . In view of our results and the declining number of invasive procedures performed, centralization in a few centers by experienced operators seems appropriate, increasing the minimal caseload per year per operator.
We suggest that, in the future, similar to The Fetal Medicine Foundation's audit for nuchal translucency, the development of an individual quality-control program for invasive procedures should be considered, taking into account numbers, efficiency and safety 5, 7, 32, 33 . The real question is whether the operator's FLR should be mentioned when counseling women regarding their choices in prenatal screening methods.
In conclusion, procedure-related pregnancy loss after invasive procedures performed transabdominally (CVS and amniocentesis) or transcervically (CVS with forceps) are lower than reported previously when performed by experienced operators.
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